Yes, GlaxoSmithKline completed a massive asset swap and corporate transaction agreement with Novartis in which GSK divested its entire oncology business portfolio to Novartis for an aggregate cash consideration of 16 billion dollars. This major strategic realignment allowed GSK to focus heavily on its core vaccine and consumer healthcare segments while enabling Novartis to expand its global oncology footprint.